TY - JOUR T1 - 临床肺清除指数的纵向课程儿童患有囊性纤维化JF - 欧洲呼吸杂志JO - 欧洲呼吸j执行 - 10.1183 / 13993003.02686-2020 SP - 2002686 AU - Frauchiger，贝蒂娜S. AU - Binggeli，塞韦林AU- Yammine，苏菲AU - 斯派切尔，本AU - 克鲁格，属非盟 - 拉姆齐，凯瑟琳A. AU - Latzin，菲利普Y1 - 2020年1月1日UR - //www.qdcxjkg.com/content/early/2020/12/10/13993003.02686-2020.abstract N2 - 理由虽然肺清除指数（LCI）是小气道疾病的囊性纤维化（CF）的个体敏感标记物，较少有人知道常规临床监测期间在LCI纵向变化。Objectives To describe the longitudinal course of LCI in children with CF during routine clinical surveillance and assess influencing factors.Methods Children with CF aged 3–18 years performed LCI measurements every 3 months as part of routine clinical care between 2011 and 2018. We recorded clinical data at every visit. We used a multilevel mixed-effect model to determine changes in LCI over time and identify clinical factors that influence LCI course.Measurements and Main Results We collected LCI from 1204 visits (3603 trials) in 78 participants, of which 907 visits had acceptable LCI data. The average unadjusted increase in LCI for the entire population was 0.29 LCI units·year−1 (95% CI 0.20–0.38). The increase in LCI was more pronounced in adolescence, with 0.41 units·year−1 (95% CI 0.27–0.54). Colonisation with either Pseudomonas aeruginosa or Aspergillus fumigatus, pulmonary exacerbations, CF-related diabetes, and bronchopulmonary aspergillosis were associated with a higher increase in LCI over time. Adjusting for clinical risk factors reduced the increase in LCI over time to 0.24 LCI units·year−1 (95% CI 0.16–0.33).Conclusion LCI measured during routine clinical surveillance is associated with underlying disease progression in children with CF. An increased change in LCI over time should prompt further diagnostic intervention.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Frauchiger has nothing to disclose.Conflict of interest: Dr. Binggeli has nothing to disclose.Conflict of interest: Dr. Yammine reports grants from Swiss National Science Foundation, outside the submitted work.Conflict of interest: Dr. Spycher reports grants from Swiss National Science Foundation, grants from Swiss Cancer League, outside the submitted work.Conflict of interest: Dr. Krüger has nothing to disclose.Conflict of interest: Dr. Ramsey reports grants from Swiss National Science Foundation, outside the submitted work.Conflict of interest: Dr. Latzin reports grants from Vertex, during the conduct of the study; personal fees from Vertex, personal fees from Novartis, personal fees from Roche, personal fees from Polyphor, personal fees from Vifor, personal fees from Gilead, personal fees from Schwabe, personal fees from Zambon, personal fees from Santhera, grants from Vertex, outside the submitted work. ER -